No headlines found.
Globe Newswire (Thu, 28-May 7:25 AM ET)
Dyadic to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Globe Newswire (Thu, 21-May 4:05 PM ET)
Globe Newswire (Thu, 21-May 3:45 PM ET)
Sidoti Events, LLC's May Micro-Cap Virtual Conference
ACCESS Newswire (Wed, 20-May 7:30 AM ET)
Dyadic Applied BioSolutions Announces Participation in Sidoti Virtual Investor Conference
Globe Newswire (Tue, 19-May 9:35 AM ET)
Dyadic Announces First Quarter 2026 Financial Results and Highlights Recent Company Progress
Globe Newswire (Wed, 13-May 4:05 PM ET)
Dyadic to Report Q1 2026 Financial Results and Host Conference Call on Wednesday May 13, 2026
Globe Newswire (Wed, 29-Apr 4:05 PM ET)
Dyadic Announces 2025 Financial Results and Highlights Recent Company Progress
Globe Newswire (Wed, 25-Mar 4:51 PM ET)
Dyadic Applied BioSolutions Announces Commercial Distribution Partnership with IBT Bioservices
Globe Newswire (Mon, 16-Mar 7:20 AM ET)
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
Globe Newswire (Fri, 13-Mar 8:35 AM ET)
Dyadic International Inc is a biotechnology platform company. It has developed a gene expression platform for producing commercial quantities of industrial enzymes and other proteins and has licensed this technology to third parties, such as Abengoa Bioenergy, BASF, Codexis and others, for use in industrial (non-pharmaceutical) applications. This technology is based on the Thermothelomyces heterothallica fungus, which the company named C1.
Dyadic International trades on the NASDAQ stock market under the symbol DYAI.
As of June 11, 2026, DYAI stock price declined to $0.68 with 252,784 million shares trading.
DYAI has a beta of 2.02, meaning it tends to be more sensitive to market movements. DYAI has a correlation of 0.12 to the broad based SPY ETF.
DYAI has a market cap of $24.86 million. This is considered a Sub-Micro Cap stock.
Last quarter Dyadic International reported $1 million in Revenue and -$.05 earnings per share. This beat revenue expectation by $124,120 and missed earnings estimates by -$.02.
In the last 3 years, DYAI traded as high as $2.67 and as low as $.65.
The top ETF exchange traded funds that DYAI belongs to (by Net Assets): VTI, VXF, IWC.
DYAI has underperformed the market in the last year with a price return of -31.1% while the SPY ETF gained +23.6%. DYAI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -17.8% and -10.2%, respectively, while the SPY returned +9.2% and -1.7%, respectively.
DYAI support price is $.68 and resistance is $.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DYAI shares will trade within this expected range on the day.